Aurobindo Pharma Limited has informed the Exchange regarding Reappointment of Ernst & Young LLP as Internal Auditors of the company w.e.f. Jun 01, 2026.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma's Board of Directors has reappointed Ernst & Young LLP (EY) as Internal Auditors for the period from June 2026 to May 2027. The decision was approved at the board meeting held on May 21, 2026. EY is a global professional services firm that provides internal audit services including risk assessment, process improvement, regulatory compliance, and governance support. This is a routine annual reappointment required under corporate governance norms, with the prior engagement expiring in May 2026.
This is a standard compliance disclosure with no direct impact on the company's operations or financials. The continuity with a Big 4 audit firm reflects stable corporate governance practices but is not expected to materially influence the stock price.